{"id":"folfoxiri","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Neutropenia"},{"rate":"40-50","effect":"Diarrhea"},{"rate":"30-40","effect":"Nausea/vomiting"},{"rate":"30-40","effect":"Anemia"},{"rate":"20-30","effect":"Peripheral neuropathy"},{"rate":"15-25","effect":"Mucositis"},{"rate":"30-40","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FOLFOXIRI combines 5-fluorouracil (5-FU), leucovorin (folinic acid), oxaliplatin, and irinotecan. 5-FU and leucovorin inhibit thymidylate synthase to disrupt DNA synthesis; oxaliplatin forms DNA cross-links; and irinotecan inhibits topoisomerase I. The synergistic triple-agent approach targets multiple pathways of DNA damage and replication, enhancing cytotoxic effects against rapidly dividing cancer cells.","oneSentence":"FOLFOXIRI is a combination chemotherapy regimen that simultaneously inhibits DNA synthesis and repair through three complementary cytotoxic agents.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:13:15.218Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Locally advanced colorectal cancer"}]},"trialDetails":[{"nctId":"NCT05863195","phase":"PHASE3","title":"Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-10-19","conditions":"Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8","enrollment":408},{"nctId":"NCT07472868","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"J. W. A. Burger","startDate":"2026-03-03","conditions":"Locally Advanced Rectal Carcinoma","enrollment":394},{"nctId":"NCT06951503","phase":"PHASE3","title":"AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Akeso","startDate":"2025-05-27","conditions":"Colorectal Adenocarcinoma","enrollment":560},{"nctId":"NCT07184047","phase":"","title":"Frailty Scales for Predicting Chemotherapy Toxicity in Older Adults With Gastrointestinal Cancers","status":"COMPLETED","sponsor":"Ankara Etlik City Hospital","startDate":"2024-01-15","conditions":"Gastrointestinal Cancers, Frailty, Sarcopenia in Elderly","enrollment":72},{"nctId":"NCT05062889","phase":"PHASE2","title":"Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients","status":"SUSPENDED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2023-05-17","conditions":"Stage II Colon Cancer, Stage III Colon Cancer, HER2-positive Colon Cancer","enrollment":477},{"nctId":"NCT07094893","phase":"PHASE4","title":"Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2026-04-15","conditions":"Colorectal Cancer","enrollment":280},{"nctId":"NCT07229846","phase":"PHASE2","title":"A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation","status":"NOT_YET_RECRUITING","sponsor":"Yanqiao Zhang","startDate":"2026-02","conditions":"Colorectal Cancer","enrollment":30},{"nctId":"NCT07277842","phase":"PHASE3","title":"PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-12-29","conditions":"Locally Advanced Low Rectal Adenocarcinoma, pMMR (Microsatellite Stable Rectal Cancer)","enrollment":382},{"nctId":"NCT06733038","phase":"PHASE3","title":"FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2024-11-15","conditions":"Colorectal Cancer","enrollment":238},{"nctId":"NCT05358704","phase":"PHASE2","title":"Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer","status":"SUSPENDED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2022-05-13","conditions":"Cancer of Rectum","enrollment":38},{"nctId":"NCT01941641","phase":"PHASE2","title":"Colon Neoadjuvant FOLFOXIRI Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2013-10-09","conditions":"Rectal Cancer","enrollment":40},{"nctId":"NCT03997435","phase":"PHASE2","title":"FOLFOXIRI With or Without Intensification for Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"CCTU","startDate":"2019-09-10","conditions":"Rectal Cancer","enrollment":72},{"nctId":"NCT05382442","phase":"PHASE2","title":"A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2022-06-27","conditions":"Metastatic Colorectal Cancer","enrollment":254},{"nctId":"NCT04325425","phase":"PHASE2","title":"Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2020-09-01","conditions":"Neuroendocrine Carcinoma","enrollment":218},{"nctId":"NCT05780684","phase":"NA","title":"Individualized Dose Escalation of 5-FU for Gastrointestinal Cancer","status":"RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2023-07-14","conditions":"Colorectal Cancer, Esophagus Cancer, Appendix Cancer","enrollment":36},{"nctId":"NCT03773367","phase":"PHASE2","title":"Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lund University Hospital","startDate":"2018-12-14","conditions":"Resectable Gastric and Gastroesophageal Junction Adenocarcinoma","enrollment":60},{"nctId":"NCT03493048","phase":"PHASE2","title":"Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2018-04-15","conditions":"Colorectal Cancer, Liver Metastases","enrollment":146},{"nctId":"NCT07070713","phase":"PHASE2","title":"Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-07-30","conditions":"Metastatic Colorectal Cancer With Left-sided Primary Tumor, Immunotherapy","enrollment":44},{"nctId":"NCT06055179","phase":"NA","title":"XCHT for Irinotecan-Induced Gut Toxicities (Randomized Controlled Trial)","status":"RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2024-03-08","conditions":"Xiao Chai Hu Tang, Irinotecan-induced Diarrhea","enrollment":98},{"nctId":"NCT07024537","phase":"PHASE2","title":"HAIP Combined With Fuquinitinib as Late-line Treatment in Patients With CRLM：A Phase 2 Single-Arm Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Meng Qiu","startDate":"2023-01-12","conditions":"Colorectal Neoplasms","enrollment":24},{"nctId":"NCT05253846","phase":"PHASE2","title":"Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2022-01-25","conditions":"Locally Advanced Rectal Cancer","enrollment":63},{"nctId":"NCT05727163","phase":"PHASE2","title":"FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-07-29","conditions":"Colorectal Cancer Metastatic","enrollment":194},{"nctId":"NCT06794086","phase":"PHASE3","title":"SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases","status":"RECRUITING","sponsor":"Jun Huang","startDate":"2025-04-10","conditions":"Colorectal Cancer, Liver Metastases","enrollment":24},{"nctId":"NCT03401294","phase":"PHASE2","title":"Conversion From Unresectable To Resectable Metastatic Colorectal Cancer.","status":"RECRUITING","sponsor":"University of Saskatchewan","startDate":"2025-05-01","conditions":"Metastatic Colorectal Cancer","enrollment":32},{"nctId":"NCT05375708","phase":"PHASE2","title":"Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer Up to 10 Metastatic Sites","status":"SUSPENDED","sponsor":"UMC Utrecht","startDate":"2025-12-01","conditions":"Metastatic Colorectal Cancer, Oligometastatic Disease","enrollment":93},{"nctId":"NCT06890624","phase":"PHASE2","title":"MFOLFOXIRI Plus PD-1 Inhibitor Vs MFOLFOX6 As Neoadjuvant Therapy for Locally Advanced Colon Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-05-01","conditions":"Colon Cancer (stage II & III)","enrollment":138},{"nctId":"NCT04072198","phase":"PHASE2","title":"Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients","status":"COMPLETED","sponsor":"Gruppo Oncologico Italiano di Ricerca Clinica","startDate":"2019-09-26","conditions":"Colorectal Cancer","enrollment":73},{"nctId":"NCT06857773","phase":"PHASE3","title":"Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy With Systemic Therapy","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2024-11-21","conditions":"Colorectal Neoplasms, Floxuridine, Liver Metastases","enrollment":306},{"nctId":"NCT04380337","phase":"PHASE2","title":"Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer","status":"COMPLETED","sponsor":"Stanford University","startDate":"2020-05-21","conditions":"Rectal Cancer","enrollment":38},{"nctId":"NCT02162563","phase":"PHASE3","title":"Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases","status":"COMPLETED","sponsor":"Dutch Colorectal Cancer Group","startDate":"2014-07","conditions":"Colorectal Cancer, Liver Metastases","enrollment":530},{"nctId":"NCT03117972","phase":"PHASE2","title":"Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2017-08-04","conditions":"Metastatic Colorectal Cancer","enrollment":54},{"nctId":"NCT06767007","phase":"PHASE2","title":"SBRT + PD-1 Antibody in Unresectable Locally Recurrent Rectal Cancer（SPARKLE）","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2025-01-06","conditions":"Unresectable Locally Recurrent Rectal Cancer","enrollment":31},{"nctId":"NCT04513951","phase":"PHASE2","title":"AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients","status":"COMPLETED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2020-04-01","conditions":"Metastatic Colorectal Cancer","enrollment":62},{"nctId":"NCT06242418","phase":"PHASE2","title":"CtDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial)","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2024-03-25","conditions":"Colon Cancer","enrollment":60},{"nctId":"NCT06405139","phase":"PHASE2","title":"Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-05-01","conditions":"Colorectal Cancer","enrollment":36},{"nctId":"NCT04607668","phase":"PHASE3","title":"Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):","status":"TERMINATED","sponsor":"G1 Therapeutics, Inc.","startDate":"2021-01-06","conditions":"Colorectal Cancer Metastatic, Myelosuppression-Adult, Chemotherapeutic Toxicity","enrollment":326},{"nctId":"NCT02705300","phase":"PHASE2","title":"Side Effects to FOLFOXIRI + Tocotrienol/Placebo as First Line Treatment of Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Vejle Hospital","startDate":"2016-05-06","conditions":"Colorectal Cancer","enrollment":70},{"nctId":"NCT06575127","phase":"PHASE2","title":"Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study","status":"RECRUITING","sponsor":"Al-Azhar University","startDate":"2024-08-17","conditions":"Neoplasm Malignant, Colon Cancer Stage 4","enrollment":60},{"nctId":"NCT04680260","phase":"PHASE2","title":"OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Karen-Lise Garm Spindler","startDate":"2021-10-25","conditions":"Colorectal Cancer, Metastatic Cancer","enrollment":350},{"nctId":"NCT02842580","phase":"PHASE2","title":"De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2016-09","conditions":"Colorectal Neoplasms","enrollment":21},{"nctId":"NCT06148402","phase":"PHASE2","title":"Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-11-08","conditions":"Unresectable/Metastatic Colorectal Cancer","enrollment":30},{"nctId":"NCT04338191","phase":"PHASE3","title":"mFOLFOXIRI Versus mFOLFOX6 as Adjuvant Chemotherapy for Locally Advanced Colorectal Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-04-01","conditions":"Colorectal Cancer","enrollment":638},{"nctId":"NCT06134765","phase":"PHASE2","title":"Bemalenograstim Alfa for the Prevention in Patients With Colorectal Cancer/Pancreatic Cancer","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-11-30","conditions":"Colorectal Cancer, Pancreatic Cancer","enrollment":89},{"nctId":"NCT05839470","phase":"PHASE2","title":"Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2023-11-19","conditions":"Colorectal Cancer","enrollment":20},{"nctId":"NCT04034459","phase":"PHASE2","title":"FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC","status":"UNKNOWN","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2016-11-25","conditions":"Metastatic Colorectal Cancer","enrollment":109},{"nctId":"NCT06048146","phase":"NA","title":"A Prospective, Multicenter Randomized Controlled Study of the Application of Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Low- and Medium-lying Rectal Cancer With Lateral Lymph Node Metastasis","status":"ENROLLING_BY_INVITATION","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2022-10-01","conditions":"Lymph Node Metastasis, Cancer of Rectum and Anus, Oxaliplatin","enrollment":180},{"nctId":"NCT06099951","phase":"PHASE2","title":"Total Neoadjuvant Treatment for pMMR Locally Advanced Low Rectal Cancer: Anti-PD-1 Antibody With FOLFOXIRI and Preoperative Radiation Therapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-11-01","conditions":"Colorectal Cancer","enrollment":53},{"nctId":"NCT05862051","phase":"NA","title":"RESOLUTE Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2021-12-14","conditions":"Colorectal Cancer, Oligometastatic Disease","enrollment":75},{"nctId":"NCT03721653","phase":"PHASE2","title":"FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients","status":"COMPLETED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2018-11-30","conditions":"Metastatic Colorectal Cancer","enrollment":218},{"nctId":"NCT05081687","phase":"PHASE3","title":"Brazilian Total Neoadjuvant Therapy Trial","status":"UNKNOWN","sponsor":"Hospital Israelita Albert Einstein","startDate":"2020-02-20","conditions":"Colorectal Neoplasms","enrollment":150},{"nctId":"NCT04169347","phase":"PHASE2","title":"FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer","status":"UNKNOWN","sponsor":"Criterium, Inc.","startDate":"2019-12-02","conditions":"Colorectal Cancer Metastatic","enrollment":27},{"nctId":"NCT05354674","phase":"","title":"Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2023-09-01","conditions":"Colorectal Cancer, Liver Metastases","enrollment":302},{"nctId":"NCT05832398","phase":"NA","title":"Precision Chemotherapy Based on Organoid Drug Sensitivity for Colorectal Cancer","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2023-05-01","conditions":"Colorectal Cancer","enrollment":186},{"nctId":"NCT01328171","phase":"PHASE2","title":"FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2011-04","conditions":"Metastatic Colorectal Cancer","enrollment":93},{"nctId":"NCT03678428","phase":"PHASE3","title":"FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM","status":"TERMINATED","sponsor":"Sun Yat-sen University","startDate":"2021-12-31","conditions":"Metastatic Colorectal Cancer, Liver Metastases","enrollment":92},{"nctId":"NCT03251612","phase":"PHASE2","title":"Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Vejle Hospital","startDate":"2017-09-22","conditions":"Colorectal Cancer Metastatic","enrollment":90},{"nctId":"NCT05427669","phase":"PHASE3","title":"Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD)","status":"NOT_YET_RECRUITING","sponsor":"Yanhong Deng","startDate":"2022-10-09","conditions":"Colorectal Cancer","enrollment":340},{"nctId":"NCT05362825","phase":"","title":"Surgery Outcome Treated by Neo-adjuvant Combination of Oxaliplatin, Irinotecan, Folinic Acid and Fluorouracil (FOLFOXIRI) Regimen in Synchronous Liver Limited Metastasis Colorectal Cancer","status":"UNKNOWN","sponsor":"Cho Ray Hospital","startDate":"2022-02-18","conditions":"Liver Metastasis Colon Cancer, Synchronous Neoplasm","enrollment":89},{"nctId":"NCT05353582","phase":"PHASE2","title":"Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-06-01","conditions":"Colorectal Neoplasms, Colorectal Cancer, Colorectal Cancer Metastatic","enrollment":168},{"nctId":"NCT05316818","phase":"PHASE2","title":"Triplet (FOLFOXIRI) vs. Doublet (FOLFOX or FOLFIRI) Regimen as a 1st Line Treatment in Metastatic Colorectal Carcinoma","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","startDate":"2018-01-16","conditions":"Metastatic Colorectal Cancer","enrollment":64},{"nctId":"NCT05201430","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2021-08-27","conditions":"Rectal Cancer","enrollment":300},{"nctId":"NCT05200299","phase":"PHASE2","title":"mFOLFOXIRI Compared to mFOLFOX6 or CapeOx as Adjuvant Chemotherapy for Stage IIIB or IIIC Colorectal Cancer","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2022-02-01","conditions":"Colorectal Cancer","enrollment":100},{"nctId":"NCT05194878","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-12-01","conditions":"Colon Cancer Stage II, Colon Cancer Stage III","enrollment":840},{"nctId":"NCT05018182","phase":"PHASE2","title":"FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2021-08-02","conditions":"High-risk Locally Advanced Colorectal Cancer, Neoadjuvant Chemotherapy, FOLFOXIRI Regimen","enrollment":69},{"nctId":"NCT04358354","phase":"PHASE3","title":"Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer","status":"UNKNOWN","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2020-10-22","conditions":"Metastatic Gastric Cancer","enrollment":388},{"nctId":"NCT04852250","phase":"","title":"Centralized Tumour Board and Secondary Intervention Rate in mCRC","status":"UNKNOWN","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2021-06-01","conditions":"Metastatic Colorectal Cancer, RAS Mutation, Multidisciplinary Communication","enrollment":130},{"nctId":"NCT03484195","phase":"PHASE2","title":"Neoadjuvant FOLFOXIRI Chemotherapy in Patients With Locally Advanced Colon Cancer","status":"UNKNOWN","sponsor":"China Medical University, China","startDate":"2018-04-01","conditions":"Colonic Neoplasms, Drug Therapy","enrollment":30},{"nctId":"NCT03487939","phase":"PHASE2","title":"Neoadjuvant FOLFOXIRI Chemotherapy in Resectable Liver Metastasis of Colorectal Cancer","status":"UNKNOWN","sponsor":"China Medical University, China","startDate":"2018-05-01","conditions":"Colorectal Neoplasms, Drug Therapy","enrollment":30},{"nctId":"NCT03484221","phase":"PHASE2","title":"Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer","status":"UNKNOWN","sponsor":"China Medical University, China","startDate":"2018-04-01","conditions":"Rectal Neoplasms, Drug Therapy, Radiation","enrollment":30},{"nctId":"NCT02217020","phase":"PHASE2","title":"Neoadjuvant FOLFOXIRI Chemotherapy Alone for Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2014-08-15","conditions":"Rectal Cancer","enrollment":100},{"nctId":"NCT04838496","phase":"PHASE2","title":"Induction Chemotherapy for Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Catharina Ziekenhuis Eindhoven","startDate":"2021-06-01","conditions":"Rectal Cancer","enrollment":128},{"nctId":"NCT04832776","phase":"PHASE2","title":"FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-04-17","conditions":"Liver Metastasis Colon Cancer","enrollment":160},{"nctId":"NCT02015923","phase":"PHASE4","title":"Resection vs no Resection of the Primary in Colorectal Cancer With Unresectable Metastases","status":"TERMINATED","sponsor":"Hospital Universitari de Bellvitge","startDate":"2013-12","conditions":"Colonic Cancer, Unresectable Metastasis Originating in Colonic Cancer","enrollment":107},{"nctId":"NCT04734249","phase":"PHASE2","title":"Second-line Surufatinib Combined With Chemotherapy in Advanced CRC","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2021-03","conditions":"Advanced Colorectal Cancer","enrollment":56},{"nctId":"NCT03443661","phase":"PHASE2","title":"Neoadjuvant Triplet Chemotherapy Regimen in Patients With Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"Aiping Zhou","startDate":"2016-02-06","conditions":"Locally Advanced Rectal Cancer","enrollment":50},{"nctId":"NCT03641976","phase":"PHASE2","title":"A Study of Bevacizumab, Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (A-FOLFOXIRI) Compared With Bevacizumab, Infusional Fluorouracil, Leucovorin, and Irinotecan/Oxaliplatin (A-FOLFIRI/FOLFOX) as First-line Treatment for Metastatic Right-sided Colon Cancer","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2019-01-03","conditions":"Unresectable Metastatic Right-sided Colon Cancer Starting First-line Combination Chemotherapy, Unresectable Metastatic Right-sided Colon Cancer, Stage IV","enrollment":120},{"nctId":"NCT02497157","phase":"PHASE2","title":"Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","startDate":"2015-05-21","conditions":"Metastatic Colorectal Cancer","enrollment":45},{"nctId":"NCT02063529","phase":"PHASE2","title":"FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2014-02","conditions":"Metastatic Colorectal Cancer","enrollment":101},{"nctId":"NCT02339116","phase":"PHASE3","title":"Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC","status":"UNKNOWN","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2015-02-26","conditions":"Metastatic Colorectal Cancer","enrollment":654},{"nctId":"NCT04170530","phase":"PHASE2","title":"Neoadjuvant mFOLFOXIRI Chemotherapy Alone for Extramural Vascular Invasion Positive Locally Advanced Rectal Cancer","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2019-01-01","conditions":"Locally Advanced Rectal Cancer","enrollment":51},{"nctId":"NCT04097444","phase":"PHASE2","title":"CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC","status":"UNKNOWN","sponsor":"Chugai Pharmaceutical","startDate":"2019-10-11","conditions":"Metastatic Colorectal Cancer","enrollment":112},{"nctId":"NCT01650428","phase":"PHASE2","title":"Bevacizumab And Combination Chemotherapy in Rectal Cancer Until Surgery","status":"COMPLETED","sponsor":"University College, London","startDate":"2013-04","conditions":"Rectal Cancer","enrollment":20},{"nctId":"NCT01802645","phase":"PHASE2","title":"Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases","status":"UNKNOWN","sponsor":"Technische Universität Dresden","startDate":"2013-03","conditions":"Colorectal Cancer","enrollment":91},{"nctId":"NCT03161574","phase":"PHASE2","title":"FOLFOXIRI Chemotherapy Alone as Neoadjuvant Treatment for Circumferential Radial Margin (CRM) Positive Rectal Cancer","status":"WITHDRAWN","sponsor":"Guangxi Medical University","startDate":"2017-08-11","conditions":"Rectal Cancer","enrollment":""},{"nctId":"NCT03975049","phase":"PHASE3","title":"Triplet Combination or Doublet Regimen Versus Chemoradiation as Neoadjuvant Therapy for Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2019-08","conditions":"Rectal Cancer, Chemotherapy Effect","enrollment":933},{"nctId":"NCT01640405","phase":"PHASE3","title":"Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells","status":"COMPLETED","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","startDate":"2012-07","conditions":"Metastatic Colorectal Cancer","enrollment":350},{"nctId":"NCT03711240","phase":"PHASE2","title":"The Efficacy of Bevacizumab Combined With m-FOLFOXIRI in Borderline Resectable Colorectal Liver Metastases","status":"UNKNOWN","sponsor":"National Cheng-Kung University Hospital","startDate":"2019-01-08","conditions":"Colorectal Cancer","enrollment":40},{"nctId":"NCT03671252","phase":"PHASE3","title":"Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Combined With Long-term Radiation","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2018-11-16","conditions":"Rectal Cancer","enrollment":776},{"nctId":"NCT03504618","phase":"","title":"Research on the Treatment of Metastatic Colon Cancer Patients Treated by FOLFOXIRI","status":"COMPLETED","sponsor":"Hanoi Medical University","startDate":"2017-01-01","conditions":"Colorectal Cancer","enrollment":39},{"nctId":"NCT03222089","phase":"PHASE2","title":"Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC","status":"WITHDRAWN","sponsor":"Fujian Cancer Hospital","startDate":"2017-07-20","conditions":"Metastatic Colorectal Cancer","enrollment":""},{"nctId":"NCT03085992","phase":"PHASE2","title":"Folfoxiri Plus Bevacizumab Followed by Chemoradiotherapy Plus Bevacizumab in Patients With Resectable Rectal Cancer","status":"COMPLETED","sponsor":"Azienda Ospedaliero, Universitaria Pisana","startDate":"2012-03","conditions":"Rectal Cancer","enrollment":49},{"nctId":"NCT03391843","phase":"PHASE2","title":"Neoadjuvant Chemotherapy Combined With Cetuximab for EGFR Wild Type Locally Advanced Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"RenJi Hospital","startDate":"2017-12-01","conditions":"Rectal Cancer Stage III","enrollment":100},{"nctId":"NCT02942563","phase":"PHASE2","title":"Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2016-11-01","conditions":"Rectal Cancer","enrollment":100},{"nctId":"NCT02271464","phase":"PHASE2","title":"Maintenance Bevacizumab Only or Bevacizumab Plus Metronomic Chemotherapy in Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"Azienda Ospedaliero, Universitaria Pisana","startDate":"2012-03","conditions":"Metastatic Colorectal Cancer","enrollment":232},{"nctId":"NCT01765582","phase":"PHASE2","title":"Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2013-01-23","conditions":"Colorectal Neoplasms","enrollment":280},{"nctId":"NCT02175654","phase":"PHASE2","title":"Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab","status":"TERMINATED","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","startDate":"2014-06","conditions":"Colorectal Neoplasms, Metastatic Disease","enrollment":15},{"nctId":"NCT02246049","phase":"PHASE2","title":"A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC","status":"COMPLETED","sponsor":"EPS Corporation","startDate":"2014-05","conditions":"Colorectal Neoplasms","enrollment":69},{"nctId":"NCT00778102","phase":"PHASE2","title":"A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-10","conditions":"Colorectal Cancer","enrollment":80},{"nctId":"NCT00940303","phase":"PHASE2","title":"OPAL Study: A Study of Avastin (Bevacizumab) in Combination With FOLFOXIRI in Patients With Previously Untreated Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-06","conditions":"Colorectal Cancer","enrollment":97},{"nctId":"NCT02350530","phase":"PHASE2","title":"FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-01","conditions":"Metastatic Colorectal Cancer","enrollment":138}],"_emaApprovals":[],"_faersSignals":[{"count":4,"reaction":"DIARRHOEA"},{"count":3,"reaction":"PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME"},{"count":2,"reaction":"NAUSEA"},{"count":2,"reaction":"NEUTROPENIA"},{"count":2,"reaction":"STOMATITIS"},{"count":2,"reaction":"VOMITING"},{"count":1,"reaction":"AGRANULOCYTOSIS"},{"count":1,"reaction":"ALOPECIA"},{"count":1,"reaction":"ANAEMIA"},{"count":1,"reaction":"ARTHRALGIA"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Irinotecan","Oxaliplatin","Leucovorin","5-Fluorouracil","5-Fu"],"phase":"phase_3","status":"active","brandName":"FOLFOXIRI","genericName":"FOLFOXIRI","companyName":"Centre Hospitalier Universitaire de Besancon","companyId":"centre-hospitalier-universitaire-de-besancon","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FOLFOXIRI is a combination chemotherapy regimen that simultaneously inhibits DNA synthesis and repair through three complementary cytotoxic agents. Used for Metastatic colorectal cancer, Locally advanced colorectal cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":12,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}